Therillume

Therillume (“TLM” or the “Company”) is a clinical-stage neuro-oncology therapeutics company with an initial focus on glioblastoma (GBM) and Neurofibromatosis Type 1 and 2 (“NF1 and NF2”). Therillume is a human therapeutic spinout company from Recombinetics Inc. (“RCI”), leveraging its pioneering precise gene-editing platform to identify, validate and expedite high quality candidates through clinical development. In addition, Therillume is amassing a powerful consortium of KOL’s and leading institutions to advance novel and innovative therapies in neuro-oncology. The Company expects to enter the clinic in 2022 with therapies that have demonstrated safety and efficacy in human cancer clinical trials. Therillume is currently seeking Seed and Series A financing and strategic partners.